Table 3.

Summary of adverse events (overall study population)

Outcome	Number of patients (%)
		N = 103
	All grades	Grade 3 or 4	Grade 5
TEAEs	99 (96)	38 (37)	3 (3)
Study drug-related TEAEs	87 (84)	16 (16)	0
Related TEAEs with rate ≥ 10%
Decreased white blood cell count	17 (17)	0	0
Asthenia	17 (17)	0	0
Rash	16 (16)	1 (1)	0
Hypothyroidism	16 (16)	0	0
Hyperthyroidism	12 (12)	0	0
Decreased neutrophil count	12 (12)	1 (1)	0
Anemia	12 (12)	5 (5)	0
SAEs	27 (26)	20 (19)	3 (3)
Related SAEs	10 (10)	9 (9)	0
Related TEAEs leading to discontinuation	3 (3)	3 (3)	0
irAEs	44 (43)	8 (8)	0
irAEs leading to discontinuation	3 (3)	3 (3)	0
Injection site reactions	9 (9)	0	0
Injection site pain	2 (2)	0	0
Injection site reaction	6 (6)	0	0
Injection site swelling	1 (1)	0	0

AE, adverse event; irAE, immune-related adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event